Axial Spondyloarthritis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis: Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals for AS include easing the signs and symptoms of the disease, improving physical function, preventing disability, and slowing or preventing structural damage. Tumor necrosis factor (TNF)-alpha inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi / Simponi Aria, UCB’s Cimzia, and infliximab biosimilars) can reduce disease activity in AS and are very effective for patients who require more-potent therapies beyond first-line nonsteroidal anti-inflammatory drugs (NSAIDs). The interleukin (IL)-17 inhibitors—Novartis’s Cosentyx and Eli Lilly’s Taltz—offer an alternative mechanism of action (MOA) to TNF inhibition. The novel Janus-activated kinase (JAK) inhibitor class comprises Pfizer’s Xeljanz and AbbVie’s Rinvoq, which are the only nonbiological targeted therapies for AS.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AS patients?
- How has Rinvoq been integrated into the treatment algorithm, and what is its source of business?
- What percentage of AS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of AS patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
CONTENT HIGHLIGHTS
Markets covered: United States
Key companies: AbbVie, Amgen, Janssen, UCB, Novartis, Eli Lilly
Key drugs: NSAIDs, Humira, Enbrel, Cimzia, Remicade, Simponi, Cosentyx, Taltz, Xeljanz, Rinvoq
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Table of contents
- Axial Spondyloarthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis: Ankylosing Spondylitis (US)
- Treatment Algorithms CDA Ankylosing Spondylitis US February 2023
- Treatment Algorithms CDA Ankylosing Spondylitis 2023 Dashboard
Sheema Kher, M.Pharm., Associate Healthcare Research & Data Analyst, Immune and Inflammation. Ms. Kher has much experience in the U.S. market access and payer landscape and has analyzed formulary and payer restrictions in multiple therapy areas for diverse lines of business, including commercial, HIX, managed Medicaid, state Medicaid, and Medicare. She holds a master’s degree in drug regulatory affairs from Amity University in Noida.